/term/price-to-ffo/FRA:4XC1 KalVista Pharmaceuticals (FRA:4XC1) Price-to-Funds-From-Ope
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Price-to-Funds-From-Operations

KalVista Pharmaceuticals (FRA:4XC1) Price-to-Funds-From-Operations : (As of Jun. 20, 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

KalVista Pharmaceuticals (FRA:4XC1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Price-to-Funds-From-Operations
Comparable Companies
AVTE FUSN PGEN QURE RPHM JANX THRD VIGL AURA MGTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KALV:USA
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
Website
https://www.kalvista.com
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.